TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05027204
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
Study: NCT05027204
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab, Q3W, i.v. 30 min
Study: NCT04751487
Drug: Itepekimab SAR440340
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT00028171
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04996979
Drug: Ropivacaine 0.5% Injectable Solution
Normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
Study: NCT06384833
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC (effervescent) 600mg 1 tab PO OD for 45 days
Study: NCT04599075
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Insulin Infusion
Study: NCT04599075
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous Subcutaneous Insulin Infusion (Pump)
Study: NCT04665986
Drug: Navelbine
Normalized name: Navelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
Study: NCT04665986
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 90mg/m2 on day 1, every 3 weeks
Study: NCT06581679
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
Study: NCT06531278
Drug: Irinotecan liposome
Normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Patients are planned to receive irinotecan liposomal (60 mg/m2; d1) of every cycle.~* 27 days a cycle
Study: NCT06531278
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Patients are planned to receive Adebrelimab (20 mg/kg; d1) of every cycle.~* 27 days a cycle
Study: NCT06531278
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Patients are planned to receive Oxaliplatin (85 mg/m2; d1) of every cycle.~* 27 days a cycle
Study: NCT06531278
Drug: Calcium folinate
Normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Patients are planned to receive Calcium folinate (400mg/m2; d1) of every cycle.~* 27 days a cycle
Study: NCT05005052
Drug: Vessel
Normalized name: Vesselvite
DrugBank: Sulodexide (DB06271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
Study: NCT05808322
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
Study: NCT05697614
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valproic acid is used for general epilepsy type, used in experimental group
Study: NCT05697614
Drug: Carbamazepin
Normalized name: Carbamazepin
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbamazepine is used for focal type epilepsy, used in experimental group
Study: NCT05697614
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lamotrigine is used for general epilepsy type, used in control group
Study: NCT05697614
Drug: Clobazam
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
Study: NCT05017246
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
Study: NCT05017246
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
Study: NCT05017246
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Lidocaine infusion 1 mg/kg ideal body weight (IBW)
Study: NCT00037583
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04459234
Drug: Ketamine use in CLCC sites (indication and administration protocol)
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations
Study: NCT06328049
Drug: Trilaciclib Injection
Normalized name: trilaciclib Injection
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
Study: NCT06193616
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All consenting patients treated with octreotide LAR according to Determina AIFA n. 1264 del 3 August 2018 and fulfilling the selection criteria will be collected at prespecified time-points according to the routine visits scheduled for these patients and the periodic follow-up visits till dialysis initiation as described in the AIFA indication on GU Serie Generale n.5 del 08-01-2020.
Study: NCT04873596
Drug: Nebulized dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: parturient will receive nebulized 3ug/kg dexmedetomidine.
Study: NCT04873596
Drug: Nebulized midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: parturient will receive nebulized 0.2 mg/kg midazolam.
Study: NCT04944173
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
Study: NCT01101412
Drug: Edetate Calcium Disodium
Normalized name: Edetate Calcium Disodium
DrugBank: Edetate calcium disodium anhydrous (DB14598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given through CVC or PVC.
Study: NCT01101412
Drug: Trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given through CVC or PVC
Study: NCT00002425
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004981
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004981
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004981
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06376058
Drug: Chloroprocaine 1% Injectable Solution
Normalized name: chloroprocaine 1% injectable solution
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
Study: NCT06376058
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
Study: NCT05442801
Drug: Cyclopentolate
Normalized name: Cyclopentolate
DrugBank: Cyclopentolate (DB00979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well known eye drop used for cycloplegic refraction among children.
Study: NCT05442801
Drug: Tropicamide
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well known eye drop used for cycloplegic refraction among children.
Study: NCT05623501
Drug: Dihydromyricetin
Normalized name: Dihydromyricetin
DrugBank: Dihydromyricetin (DB15645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation and lysine preparation
Study: NCT00002346
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00594373
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm/100 ml of 1% tenofovir gel vaginally daily
Study: NCT00594373
Drug: Tenofovir gel placebo
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm/100 ml of placebo gel vaginally daily
Study: NCT05680584
Drug: Hydroxyzine Pill
Normalized name: hydroxyzine Pill
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
Study: NCT06331169
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Study: NCT06331169
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Study: NCT04801511
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
Study: NCT06054035
Drug: Dapagliflozin (Forxiga®)
Normalized name: dapagliflozin Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg once daily for 2 years. Route of administration: oral.
Study: NCT06551207
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Study: NCT06551207
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w
Study: NCT05259527
Drug: Ergocalciferol Capsules
Normalized name: Ergocalciferol Capsules
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.
Study: NCT05873790
Drug: Serplulimab plus chemotherapy
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.
Study: NCT04902937
Drug: neoadjuvant and adjuvant chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guideline-based therapy of primary non-metastatic early breast carcinoma
Study: NCT05305066
Drug: Anti-IL6
Normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL6 receptor monoclonal antibodies - tocilizumab (if weight \<100 kg: 162 mg SC every other week, followed by an increase to weekly based on clinical response; if weight ≥100 kg: 162 mg SC weekly) or sarilumab (200 mg SC once every 2 weeks)
Study: NCT05806996
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
Study: NCT06045013
Drug: 5% dextrose injection
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
Study: NCT05924321
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single infusion of Carbetocin
Study: NCT05924321
Drug: Placebo and Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
Study: NCT05423132
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
Study: NCT05423132
Drug: Physiological serum injection
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
Study: NCT04789837
Drug: Cilostazol 50 MG
Normalized name: cilostazol 50 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
Study: NCT06458465
Drug: Pentoxifylline 400 MG
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Pentoxifylline 400 mg twice daily for 6 months.
Study: NCT06511765
Drug: Ropivacaine and dexamethasone injection solution
Normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Ropivacaine and dexamethasone
Study: NCT06511765
Drug: Sodium Chloride 0.9% Injection Solution
Normalized name: Sodium Chloride 0.9% Injection Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of sodium chloride 0.9%
Study: NCT06392529
Drug: Voriconazole Powder
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
Study: NCT04552795
Drug: 3TC
Normalized name: 3TC
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
Study: NCT06531837
Drug: Esketamine(Continuous infusion)
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.
Study: NCT04759196
Drug: Topamax
Normalized name: Topamax
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
Study: NCT04759196
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
Study: NCT04671589
Drug: Meropenem Injection
Normalized name: meropenem Injection
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration Intravenous meropenem 1gram every 8 hours together with standard care;~.
Study: NCT00380835
Drug: Amrubicin
Normalized name: amrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04859452
Drug: Metformin hydrochloride tablets
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Metformin hydrochloride, tablet, oral
Study: NCT04859452
Drug: Glibenclamide tablets
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Glibenclamide, tablet, oral
Study: NCT04859452
Drug: Valsartan Capsules
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Valsartan, capsule, oral
Study: NCT05856851
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm/group descriptions.
Study: NCT05549505
Drug: ARV-471
Normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT05549505
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg tablet
Study: NCT05310071
Drug: Aducanumab
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00399048
Drug: OROS hydromorphone HCL ; OxyContin
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04952350
Drug: Atorvastatin 40 Mg Oral Tablet
Normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
Study: NCT00000714
Drug: Trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06513481
Drug: Nardraparin calcium injection
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
Study: NCT05883124
Drug: Rivastigmine twice-weekly 9,5 mg/24 h
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Study: NCT05317312
Drug: MR-107A-02
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR-107A-02 oral tablet
Study: NCT05122169
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
Study: NCT05122169
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
Study: NCT05667376
Drug: curcumin gel
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcumin gel
Study: NCT05311189
Drug: HLX10, Trastuzumab and Chemotherapy
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
Study: NCT06392854
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 dose insulin infusion 4 hours
Study: NCT06213077
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
Study: NCT05807490
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07328948 will be administered as oral suspensions daily (QD) over 14 days